Table 3.
AFT models to predict survival-based endpoints.
| Variables | TR for PFS (95% CI) | TR for OS (95% CI) |
|---|---|---|
| CEA, 68 versus 3 | 0.93 (0.86–1.01) | 0.96 (0.88–1.04) |
| NLR, 5.2 versus 2.1 | 0.80 (0.70–0.92) | 0.73 (0.63–0.83) |
| ECOG PS, 0 versus 1 | 1.05 (0.88–1.24) | 1.09 (0.92–1.30) |
| ECOG PS, 2 versus 0 | 0.65 (0.53–0.81) | 0.59 (0.48–0.73) |
| Lauren subtype, diffuse versus intestinal | 0.74 (0.57–0.97) | 0.73 (0.57–0.94) |
| Lauren subtype, mixed versus intestinal | 0.64 (0.45–0.90) | 0.75 (0.52–1.08) |
| HER2, IHC +2/FISH+ versus IHC +3 | 0.83 (0.71–0.97) | 0.85 (0.73–1.00) |
| Signet-ring cells | 0.96 (0.75–1.25) | 0.97 (0.75–1.25) |
| Surgery of the primary tumour | 1.09 (0.90–1.32) | 1.07 (0.88–1.29) |
| Location, GEJ versus stomach | 0.83 (0.69–0.99) | 0.85 (0.71–1.03) |
| Location, oesophagus versus stomach | 0.77 (0.61–0.95) | 0.82 (0.66–1.03) |
| Histological grade, 3 versus 2 | 0.90 (0.74–1.08) | 0.87 (0.72–1.07) |
| Histological grade, 1 versus 2 | 1.19 (0.98–1.44) | 1.29 (1.07–1.55) |
| Age, 72 versus 56 | 0.94 (0.84–1.05) | 0.82 (0.69–1.02) |
| Tumour burden, low versus very high | 1.58 (1.25–1.99) | 1.69 (1.34–2.13) |
| Tumour burden, moderate versus very high | 1.43 (1.16–1.76) | 1.38 (1.12–1.70) |
| Tumour burden, high versus very high | 1.08 (0.91–1.28) | 1.11 (0.94–1.32) |
| Albumin 3–3.5 g/dL versus normal | 0.92 (0.76–1.13) | 0.93 (0.77–1.14) |
| Albumin <3 g/dL versus normal | 0.83 (0.64–1.07) | 0.89 (0.69–1.14) |
| Anthracycline-based regimens versus CAPOX | 1.42 (0.99–2.05) | 1.32 (0.92–1.90) |
| Carboplatin–5FU versus CAPOX | 0.74 (0.52–1.04) | 0.87 (0.61–1.22) |
| Cisplatin–5FU versus CAPOX | 0.96 (0.76–1.21) | 1.01 (0.80–1.27) |
| Docetaxel-containing regimens versus CAPOX | 1.03 (0.64–1.67) | 1.33 (0.83–2.13) |
| FOLFOX versus CAPOX | 1.38 (1.10–1.71) | 1.23 (0.99–1.53) |
| Others versus CAPOX | 0.64 (0.41–1.00) | 0.88 (0.56–1.37) |
| XP versus CAPOX | 0.89 (0.73–1.08) | 0.89 (0.73–1.08) |
The criteria for overall tumour burden are specified in Table 1. Interpretation of adjusted TRs: TR > 1 means that an increase in the value of the covariate is associated with longer survival; TR < 1 means that an increase in the value of the covariate is associated with shorter survival. Adjusted TRs are derived from a multivariable log-normal AFT models and represent its exponentiated coefficients.
5FU, 5-fluorouracil; AFT, accelerated failure time; CAPOX, capecitabine/oxaliplatin; CEA, carcinoembryonic antigen; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridisation; FOLFOX, 5-fluorouracil/oxaliplatin; GEJ, gastroesophageal junction; IHC, immunohistochemistry; OS, overall survival; PFS, progression-free survival; TR, time ratio; XP, capecitabine/cisplatin.